Moderna, Inc.

MRNA Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.

218.01 18.49 −7.82%
Market cap
$94.4B
P/E
0.0×
Fwd P/E
−5.5×
Dividend yield
—
F-score
3/9
Altman Z
2.46
Beneish M
−3.52
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

2 3 1 1
ROE
(29.32%) (28.87%) (36.56%) (39.00%)
ROA
(22.31%) (21.31%) (26.41%) (27.43%)
ROIC
(44.61%) (55.51%) (76.00%) (93.47%)
Return on Tangible Assets
(44.24%) (42.18%) (58.49%) (59.01%)
Average Days of Receivables
171.05 34.55 11.65 2.79
Free Cash Flow per Share
(6.83) (5.33) (4.06) (3.13)
Free Cash Flow
(2,663.00) (2,075.00) (1,603.00) (1,244.00)
Other line items

Show all line items

Columns are period end dates